Raveron® versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Bircan, K.; ÖZEN, HASAN; Ergen, A.; Başar, I.; Özgür, S.; Ilker, Y.; Karaaĝaoĝlu, AHMET; Remzi, D.

doi:10.1007/bf02549794

Raveron® versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Bircan K., ÖZEN H., Ergen A., Başar I., Özgür S., Ilker Y., ...Daha Fazla

International Urology and Nephrology, cilt.22, sa.4, ss.345-348, 1990 (Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 4
Basım Tarihi: 1990
Doi Numarası: 10.1007/bf02549794
Dergi Adı: International Urology and Nephrology
Derginin Tarandığı İndeksler: Scopus
Sayfa Sayıları: ss.345-348
Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Thirty patients with BPH were randomized into two groups to receive Raveron® and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron® and placebo. © 1990 Akadémiai Kiadó.